All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Between 34% and 41% of patients with polycythemia vera (PV) experience thrombotic events (TE). Established risk factors for TE include JAK2 mutation, advanced age, TE history, and elevated hematocrit.1 In addition, retrospective studies have shown elevated white blood cell (WBC) count to be associated with increased TE risk.1 Here, we summarize a prospective, observational study by Gerds et al.1 published in Blood which investigated association between WBC count and TE in patients with PV enrolled in the REVEAL study.1
Table 1. REVEAL: Blood counts and associated TE risk*
HCT, hematocrit level; HR, hazard ratio; NEUT, absolute neutrophil count; NS, not significant; PLT, platelet; TE, thrombotic event; WBC, white blood cell count.
*Adapted from Gerds, et al.1
†Association significance was not sustained a year after initial assessment.
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox